Global Non-Small Cell Lung Cancer Patient Insights and Epidemiology - 2016

  • ID: 3692056
  • Report
  • Region: Global
  • 110 pages
  • Epipatients
1 of 3
The latest survey Global Non-Small Cell Lung Cancer Patient Insights and Epidemiology – 2016, provides insights into total Non-Small Cell Lung Cancer patients on drug therapies in top 7 markets, Non-Small Cell Lung Cancer treatable patients, and Non-Small Cell Lung Cancer epidemiology in top 7 markets. Epipatients conducted an online survey with Non-Small Cell Lung Cancer specialists, oncologists, and Non-Small Cell Lung Cancer patients to identify the Non-Small Cell Lung Cancer patients in top 7 markets who were treated by drug therapies. The research also identifies total Non-Small Cell Lung Cancer patients’ on drug therapies by Non-Small Cell Lung Cancer stages.
Non-Small Cell Lung cancer patients were given chemotherapies, targeted therapies, and immunotherapies as a part of their treatment. This study accurately determines and forecast Non-Small Cell Lung Cancer patients who were on drug therapies in a given year. This research also provides insights into Non-Small Cell Lung Cancer epidemiology including Non-Small Cell Lung Cancer incidence and Non-Small Cell Lung Cancer prevalence by Non-Small Cell Lung Cancer stages I-IV.

Key Questions Answered:
- Countries: US, Japan, Germany, France, Italy, Spain, UK
- Non-Small Cell Lung Cancer Incidence in top 7 markets by staging – Stage I, Stage II, Stage III, and Stage IV
- Non-Small Cell Lung Cancer Prevalence in top 7 markets (10-year) by staging – Stage I, Stage II, Stage III, and Stage IV
- Non-Small Cell Lung Cancer Treatable Patients in top 7 markets by staging – Stage I, Stage II, Stage III, and Stage IV
- Non-Small Cell Lung Cancer Patients on drug therapies by stages – Stage I, Stage II, Stage III, and Stage IV
- Base Year – 2015, Historic from 2010 and forecast to 2025

Key Benefits:
This research will help analysts, healthcare providers, pharmaceutical companies, epidemiologists, clinical research organizations, universities, government agencies, and insurers to determine their study population. This research will help executives estimate Non-Small Cell Lung Cancer market potential, Non-Small Cell Lung Cancer drug therapies market potential, assess unmet need, patient share, market share, develop forecasting models, and build patient-based health management frameworks. The data presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Methodology
2. Non-Small Cell Lung Cancer Patients Globally by Stages
2.1. Incidence
2.2. Prevalence
2.3. Treatable Patients
2.4. Patients on drug therapies
3. Non-Small Cell Lung Cancer Patients in Germany by Stages
3.1. Incidence
3.2. Prevalence
3.3. Treatable Patients
3.4. Patients on drug therapies
4. Non-Small Cell Lung Cancer Patients in France by Stages
4.1. Incidence
4.2. Prevalence
4.3. Treatable Patients
4.4. Patients on drug therapies
5. Non-Small Cell Lung Cancer Patients in Italy by Stages
5.1. Incidence
5.2. Prevalence
5.3. Treatable Patients
5.4. Patients on drug therapies
6. Non-Small Cell Lung Cancer Patients in Spain by Stages
6.1. Incidence
6.2. Prevalence
6.3. Treatable Patients
6.4. Patients on drug therapies
7. Non-Small Cell Lung Cancer Patients in UK by Stages
7.1. Incidence
7.2. Prevalence
7.3. Treatable Patients
7.4. Patients on drug therapies
8. Non-Small Cell Lung Cancer Patients in Japan by Stages
8.1. Incidence
8.2. Prevalence
8.3. Treatable Patients
8.4. Patients on drug therapies
9. Non-Small Cell Lung Cancer Patients in US by Stages
9.1. Incidence
9.2. Prevalence
9.3. Treatable Patients
9.4. Patients on drug therapies
10. Glossary

1. Non-Small Cell Lung Cancer Incidence by Stages, Global, 2010 - 2025
2. Non-Small Cell Lung Cancer Prevalence by Stages, Global, 2010 - 2025
3. Non-Small Cell Lung Cancer Treatable Patients by Stages, Global, 2010 - 2025
4. Total Non-Small Cell Lung Cancer Patients on drug therapies by Stages, Global, 2010 – 2025
5. Non-Small Cell Lung Cancer Incidence by Stages, Germany, 2010 - 2025
6. Non-Small Cell Lung Cancer Prevalence by Stages, Germany, 2010 - 2025
7. Non-Small Cell Lung Cancer Treatable Patients by Stages, Germany, 2010 - 2025
8. Total Non-Small Cell Lung Cancer Patients on drug therapies by Stages, Germany, 2010 - 2025
9. Non-Small Cell Lung Cancer Incidence by Stages, France, 2010 - 2025
10. Non-Small Cell Lung Cancer Prevalence by Stages, France, 2010 - 2025
11. Non-Small Cell Lung Cancer Treatable Patients by Stages, France, 2010 - 2025
12. Total Non-Small Cell Lung Cancer Patients on drug therapies by Stages, France, 2010 - 2025
13. Non-Small Cell Lung Cancer Incidence by Stages, Italy, 2010 - 2025
14. Non-Small Cell Lung Cancer Prevalence by Stages, Italy, 2010 - 2025
15. Non-Small Cell Lung Cancer Treatable Patients by Stages, Italy, 2010 - 2025
16. Total Non-Small Cell Lung Cancer Patients on drug therapies by Stages, Italy, 2010 - 2025
17. Non-Small Cell Lung Cancer Incidence by Stages, Spain, 2010 - 2025
18. Non-Small Cell Lung Cancer Prevalence by Stages, Spain, 2010 - 2025
19. Non-Small Cell Lung Cancer Treatable Patients by Stages, Spain, 2010 - 2025
20. Total Non-Small Cell Lung Cancer Patients on drug therapies by Stages, Spain, 2010 - 2025
21. Non-Small Cell Lung Cancer Incidence by Stages, UK, 2010 - 2025
22. Non-Small Cell Lung Cancer Prevalence by Stages, UK, 2010 - 2025
23. Non-Small Cell Lung Cancer Treatable Patients by Stages, UK, 2010 - 2025
24. Total Non-Small Cell Lung Cancer Patients on drug therapies by Stages, UK, 2010 – 2025
25. Non-Small Cell Lung Cancer Incidence by Stages, Japan, 2010 - 2025
26. Non-Small Cell Lung Cancer Prevalence by Stages, Japan, 2010 - 2025
27. Non-Small Cell Lung Cancer Treatable Patients by Stages, Japan, 2010 - 2025
28. Total Non-Small Cell Lung Cancer Patients on drug therapies by Stages, Japan, 2010 – 2025
29. Non-Small Cell Lung Cancer Incidence by Stages, US, 2010 - 2025
30. Non-Small Cell Lung Cancer Prevalence by Stages, US, 2010 - 2025
31. Non-Small Cell Lung Cancer Treatable Patients by Stages, US 2010 - 2025
32. Total Non-Small Cell Lung Cancer Patients on drug therapies by Stages, US, 2010 - 2025

1. Non-Small Cell Lung Cancer Incidence, Global, 2010 – 2025
2. Non-Small Cell Lung Cancer Incidence – Stage I, Global, 2010 – 2025
3. Non-Small Cell Lung Cancer Incidence – Stage II, Global, 2010 - 2025
4. Non-Small Cell Lung Cancer Incidence – Stage III, Global, 2010 - 2025
5. Non-Small Cell Lung Cancer Incidence – Stage IV, Global, 2010 – 2025
6. Non-Small Cell Lung Cancer Prevalence, Global, 2010 - 2025
7. Non-Small Cell Lung Cancer Prevalence – Stage I, Global, 2010 – 2025
8. Non-Small Cell Lung Cancer Prevalence – Stage II, Global, 2010 - 2025
9. Non-Small Cell Lung Cancer Prevalence – Stage III, Global, 2010 - 2025
10. Non-Small Cell Lung Cancer Prevalence – Stage IV, Global, 2010 - 2025
11. Non-Small Cell Lung Cancer Treatable Patients, Global, 2010 - 2025
12. Non-Small Cell Lung Cancer Treatable Patients – Stage I, Global, 2010 – 2025
13. Non-Small Cell Lung Cancer Treatable Patients – Stage II, Global, 2010 - 2025
14. Non-Small Cell Lung Cancer Treatable Patients – Stage III, Global, 2010 - 2025
15. Non-Small Cell Lung Cancer Treatable Patients – Stage IV, Global, 2010 - 2025
16. Non-Small Cell Lung Cancer Patients on drug therapies, Global, 2010 - 2025
17. Total Non-Small Cell Lung Cancer Patients on drug therapies – Stage I, Global, 2010 – 2025
18. Total Non-Small Cell Lung Cancer Patients on drug therapies – Stage II, Global, 2010 – 2025
19. Total Non-Small Cell Lung Cancer Patients on drug therapies – Stage III, Global, 2010 – 2025
20. Total Non-Small Cell Lung Cancer Patients on drug therapies – Stage IV, Global, 2010 – 2025
21. Non-Small Cell Lung Cancer Incidence by Stages, Germany, 2010 – 2025
22. Non-Small Cell Lung Cancer Prevalence by Stages, Germany, 2010 – 2025
23. Non-Small Cell Lung Cancer Treatable Patients by Stages, Germany, 2010 – 2025
24. Non-Small Cell Lung Cancer Patients on drug therapies, Germany, 2010 - 2015
25. Non-Small Cell Lung Cancer Incidence by Stages, France, 2010 – 2025
26. Non-Small Cell Lung Cancer Prevalence by Stages, France, 2010 – 2025
27. Non-Small Cell Lung Cancer Treatable Patients by Stages, France, 2010 – 2025
28. Non-Small Cell Lung Cancer Patients on drug therapies, France, 2010 – 2025
29. Non-Small Cell Lung Cancer Incidence by Stages, Italy, 2010 – 2025
30. Non-Small Cell Lung Cancer Prevalence by Stages, Italy, 2010 – 2025
31. Non-Small Cell Lung Cancer Treatable Patients by Stages, Italy, 2010 – 2025
32. Non-Small Cell Lung Cancer Patients on drug therapies, Italy, 2010 – 2025
33. Non-Small Cell Lung Cancer Incidence by Stages, Spain, 2010 – 2025
34. Non-Small Cell Lung Cancer Prevalence by Stages, Spain, 2010 – 2025
35. Non-Small Cell Lung Cancer Treatable Patients by Stages, Spain, 2010 – 2025
36. Non-Small Cell Lung Cancer Patients on drug therapies, Spain, 2010 - 2015
37. Non-Small Cell Lung Cancer Incidence by Stages, UK, 2010 – 2025
38. Non-Small Cell Lung Cancer Prevalence by Stages, UK, 2010 – 2025
39. Non-Small Cell Lung Cancer Treatable Patients by Stages, UK, 2010 – 2025
40. Non-Small Cell Lung Cancer Patients on drug therapies, UK, 2010 – 2025
41. Non-Small Cell Lung Cancer Incidence by Stages, Japan, 2010 – 2025
42. Non-Small Cell Lung Cancer Prevalence by Stages, Japan, 2010 – 2025
43. Non-Small Cell Lung Cancer Treatable Patients by Stages, Japan, 2010 – 2025
44. Non-Small Cell Lung Cancer Patients on drug therapies, Japan, 2010 – 2025
45. Non-Small Cell Lung Cancer Incidence by Stages, US, 2010 – 2025
46. Non-Small Cell Lung Cancer Prevalence by Stages, US, 2010 – 2025
47. Non-Small Cell Lung Cancer Treatable Patients by Stages, US, 2010 – 2025
48. Non-Small Cell Lung Cancer Patients on drug therapies, US, 2010 - 2015
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll